Marcus Niemeyer
Overview
Explore the profile of Marcus Niemeyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
377
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumar A, Franek E, Wise J, Niemeyer M, Mersebach H, Simo R
PLoS One
. 2016 Oct;
11(10):e0163350.
PMID: 27760129
Purpose: The efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily (OD) compared with insulin glargine U100 (IGlar) OD over 52 weeks in insulin-naïve adults with type 2 diabetes...
2.
Pfutzner A, Forst T, Niemeyer M, Bailey T
Expert Opin Drug Deliv
. 2014 Jun;
11(9):1381-9.
PMID: 24921223
Objective: FlexTouch® (FT) is a new prefilled insulin pen with no push-button extension and a low injection force used to deliver several basal insulins, including insulin degludec across a wide...
3.
Bode B, Chaykin L, Sussman A, Warren M, Niemeyer M, Rabol R, et al.
Endocr Pract
. 2014 Feb;
20(8):785-91.
PMID: 24518180
Objective: The purpose of the present study was to provide clinical data on the efficacy and safety of insulin degludec (IDeg) 200 U/mL compared with IDeg 100 U/mL in patients...
4.
Gotzche D, Rasmussen B, Pedersen M, Sparre T, Bucher D, Niemeyer M
Expert Opin Drug Deliv
. 2013 Nov;
10(12):1613-9.
PMID: 24256325
Objective: The aim of the paper is to determine the dose accuracy and injection force of FlexTouch (FT) filled with insulin degludec 100 U/ml, insulin degludec 200 U/ml and insulin...
5.
Philis-Tsimikas A, Brod M, Niemeyer M, Ocampo Francisco A, Rothman J
Adv Ther
. 2013 Jul;
30(6):607-22.
PMID: 23812875
Introduction: Insulin degludec (IDeg) is a new basal insulin in development with a flat, ultra-long action profile that may permit dosing using a simplified titration algorithm with less frequent self-measured...
6.
Pfutzner A, Bailey T, Campos C, Kahn D, Ambers E, Niemeyer M, et al.
Curr Med Res Opin
. 2013 Feb;
29(5):475-81.
PMID: 23402225
Objectives: The primary objective of this study was to investigate the dosing accuracy of the new prefilled FlexTouch insulin pen (FT) in comparison to conventional vial and syringe (V&S) when...
7.
Oyer D, Niemeyer M, Moses A
Postgrad Med
. 2012 Oct;
124(5):110-20.
PMID: 23095431
For people with diabetes treated with insulin, the development of insulin pens has led to important advantages compared with the use of vials and syringes. Insulin pens are associated with...
8.
Pfutzner A, Schipper C, Niemeyer M, Qvist M, Loffler A, Forst T, et al.
J Diabetes Sci Technol
. 2012 Aug;
6(4):910-6.
PMID: 22920818
Background: Impaired dexterity has been reported to be prevalent in diabetes patients independent from the existence of diabetic neuropathy. This study was performed to investigate the impact of dexterity impairment...
9.
Schipper C, Musholt P, Niemeyer M, Qvist M, Loffler A, Forst T, et al.
Curr Med Res Opin
. 2012 Jul;
28(8):1297-303.
PMID: 22746353
Objective: FT (FlexTouch*) is a new disposable insulin injection pen device for use in insulin-treated patients with diabetes mellitus. The aim of this study was to evaluate patient perception of...
10.
Nadeau D, Campos C, Niemeyer M, Bailey T
Curr Med Res Opin
. 2011 Nov;
28(1):3-13.
PMID: 22114905
Objective: FlexTouch * (FT) is a new prefilled insulin pen with no push-button extension at any set dose and a low activation force that is designed to improve ease of...